51 results on '"Chen, Tzu-Hsiu"'
Search Results
2. Supplementary Table 1 from Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
3. Supplementary Figure 2 from Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
4. Supplementary Table 1 from Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
5. Supplementary Methods, Figure Legends 1-3 from Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
6. Supplementary Methods, Figure Legends 1-3 from Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
7. Data from An Integrated View of Copy Number and Allelic Alterations in the Cancer Genome Using Single Nucleotide Polymorphism Arrays
8. Supplementary Figure 3 from Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
9. Supplementary Table 2 from Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
10. Supplementary Figure 4 from Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
11. Supplementary Figure 1 from Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
12. Supplementary Figure 3 from Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
13. Supplementary Data URL from An Integrated View of Copy Number and Allelic Alterations in the Cancer Genome Using Single Nucleotide Polymorphism Arrays
14. Supplementary Figure 4 from Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
15. Supplementary Figure 1 from Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
16. Supplementary Figure 2 from Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
17. Data from An Integrated View of Copy Number and Allelic Alterations in the Cancer Genome Using Single Nucleotide Polymorphism Arrays
18. Supplementary Data URL from An Integrated View of Copy Number and Allelic Alterations in the Cancer Genome Using Single Nucleotide Polymorphism Arrays
19. Supplementary Table 2 from Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
20. Towards Efficient Neural Network on Edge Devices via Statistical Weight Pruning
21. Lightweight Super-resolution Learning Model for Extremely Exposed Images
22. RET fusions observed in lung and colorectal cancers are sensitive to ponatinib
23. Antcin-H Isolated fromAntrodia cinnamomeaInhibits Renal Cancer Cell Invasion Partly through Inactivation of FAK-ERK-C/EBP-β/c-Fos-MMP-7 Pathways
24. The Topoisomerase 1 Inhibitor Austrobailignan-1 Isolated from Koelreuteria henryi Induces a G2/M-Phase Arrest and Cell Death Independently of p53 in Non-Small Cell Lung Cancer Cells
25. Abstract 2726: RET fusions identified in colorectal cancer PDX models are sensitive to the potent RET inhibitor ponatinib
26. Corrigendum to “Luteolin attenuates TGF-β1-induced epithelial–mesenchymal transition of lung cancer cells by interfering in the PI3K/Akt–NF-κB–Snail pathway”. [Life Sci 94 (2013) 924–933]
27. Comparison of visual effects of immersion fluids for dermoscopic examination of acral volar melanocytic lesions
28. Luteolin attenuates TGF-β1-induced epithelial–mesenchymal transition of lung cancer cells by interfering in the PI3K/Akt–NF-κB–Snail pathway
29. Comprehensive Analysis Of The In Vitro Potency Of Ponatinib, and All Other Approved BCR-ABL Tyrosine Kinase Inhibitors (TKIs), Against a Panel Of Single and Compound BCR-ABL Mutants
30. Abstract B266: Ponatinib, a potent KIT inhibitor, suppresses the emergence of secondary resistance mutations in a gastrointestinal stromal tumor (GIST) model system.
31. Hepatoprotection using sweet orange peel and its bioactive compound, hesperidin, for CCl4-induced liver injury in vivo
32. Interleukin-6 upregulates paraoxonase 1 gene expression via an AKT/NF-κB-dependent pathway
33. Abstract 2084: Ponatinib is a highly potent inhibitor of activated variants of RET found in MTC and NSCLC .
34. Destruxin B Isolated from Entomopathogenic FungusMetarhizium anisopliaeInduces Apoptosis via a Bcl-2 Family-Dependent Mitochondrial Pathway in Human Nonsmall Cell Lung Cancer Cells
35. Adherence to Phosphate Binder Therapy Is the Primary Determinant of Hyperphosphatemia Incidence in Patients Receiving Peritoneal Dialysis
36. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2
37. Abstract 1: Oncogenic extracellular domain mutations of ERBB2 in cancer
38. Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
39. Abstract A199: Oncogenic and drug‐sensitive ERBB2 mutations in glioblastoma
40. Abstract A2: Oncogenic and drug-sensitive ERBB2 mutations in glioblastoma
41. Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions
42. Drug-sensitive FGFR2 mutations in endometrial carcinoma
43. Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors
44. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing
45. Study on the Composites of Two Sized Silica Filled in PTFE
46. Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants
47. An Integrated View of Copy Number and Allelic Alterations in the Cancer Genome Using Single Nucleotide Polymorphism Arrays
48. High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines
49. Soy Protein Hydrolyzate with Bound Phospholipids Reduces Serum Cholesterol Levels in Hypercholesterolemic Adult Male Volunteers
50. A Nucleoside-Nucleotide Mixture May Reduce Memory Deterioration in Old Senescence-Accelerated Mice
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.